In September 2023, Pharmasyntez-Nord JSC, which is the part of the Pharmasyntez Group of Companies, released the first lot of the drug product Myelodest (pomalidomide). The drug was registered in June, 2023 and is available in three dosage strengths: 1, 2 and 4 mg.

Myelodest belongs to the group of cytostatics and is used to treat patients with multiple myeloma aged over 18. Multiple myeloma is a malignant plasma cell neoplasm that produces monoclonal immunoglobulins that that infiltrate and destroy adjacent bone tissue. Characteristic manifestations of the disease include lytic bone lesions, fractures, renal failure, hypercalcemia, anemia, and recurrent infections. 

Myelodest is used in combination with other drugs used in the complex therapy of oncological diseases. Multiple myeloma is usually not curable. However, signs and symptoms can be significantly reduced due to a properly selected treatment regimen. The drug product Myelodest is able to affect the body’s immune system and directly the cancer cells.

According to Mikhail Kvasnikov, Chief Executive Officer of Pharmasyntez-Nord JSC, the current production volume of antineoplastic drugs at the company stands at 5.6 million packages per year.  In the spring of 2023, V. V. Putin, President of the Russian Federation, opened the second stage of the plant. Design works are underway for the construction of the third stage. Future production volumes of vital and essential medicinal products will only rise, enabling the company not only to meet the needs not only within the country, but also to be more actively represented in the pharmaceutical markets of friendly countries.

Pharmasyntez-Nord JSC (part of the Pharmasyntez Group of Companies) is a modern pharmaceutical research and manufacturing complex specializing in the development and manufacture of pharmaceutical products. Antineoplastic drugs manufactured by Pharmasyntez-Nord JSC are exported to CIS countries and the Dominican Republic.